Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CISMeF
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T LymphocytesNCIt concept
Preferred Label : Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes;
NCIt definition : A preparation of genetically modified CD8 central memory (Tcm) and CD4 autologous
T-lymphocytes (1:1) transduced with a replication incompetent, self-inactivating (SIN)
lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19
single chain variable fragment (scFv) derived from the murine IgG1 monoclonal antibody
(mAb) FMC63, fused to the signaling domain of 4-1BB (CD137), the zeta chain of the
TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor
receptor (EGFRt), with potential immunostimulating and antineoplastic activities.
Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing
T lymphocytes are directed to and induce selective toxicity in CD19-expressing tumor
cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell
lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity,
the expressed EGFRt both facilitates in vivo detection of the administered, transduced
T-cells and can promote elimination of those cells through a cetuximab-induced antibody
dependent cellular cytotoxicity response. The 4-1BB costimulatory signaling domain
enhances both proliferation of T-cells and antitumor activity.;